We are live on ! Find out more
ACHN

Achillion Pharmaceuticals
ACHN

Delisted

ACHN was delisted on the 27th of January, 2020.

147 hedge funds and large institutions have $852M invested in Achillion Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 55 increasing their positions, 44 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more call options, than puts

Call options by funds: $10M | Put options by funds: $3.6M

25% more repeat investments, than reductions

Existing positions increased: 55 | Existing positions reduced: 44

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

1% less capital invested

Capital invested by funds: $858M → $852M (-$5.15M)

4% less funds holding

Funds holding: 153147 (-6)

15% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 20

Holders
147
Holders Change
-6
Holders Change %
-3.92%
% of All Funds
3.92%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
17
Increased
55
Reduced
44
Closed
20
Calls
$10M
Puts
$3.6M
Net Calls
+$6.4M
Net Calls Change
-$4.11M
Name Holding Trade Value Shares
Change
Change in
Stake
State Board of Administration of Florida Retirement System
76
State Board of Administration of Florida Retirement System
Florida
$587K
CLOS
77
Compagnie Lombard Odier SCmA
Switzerland
$563K -$68.6K -8,000 -10%
DekaBank Deutsche Girozentrale
78
DekaBank Deutsche Girozentrale
Germany
$551K +$100K +11,700 +20%
D.E. Shaw & Co
79
D.E. Shaw & Co
New York
$538K +$427K +49,776 +259%
AIG
80
American International Group
New York
$526K -$18.7K -2,176 -3%
UBS AM
81
UBS AM
Illinois
$523K
Squarepoint
82
Squarepoint
New York
$440K +$234K +27,300 +94%
DTL
83
Dynamic Technology Lab
Singapore
$433K +$344K +40,114 +260%
VKH
84
Virtu KCG Holdings
New York
$424K +$218K +25,462 +88%
Royal Bank of Canada
85
Royal Bank of Canada
Ontario, Canada
$400K -$112K -13,004 -20%
VOYA Investment Management
86
VOYA Investment Management
Georgia
$383K
BG
87
BlackRock Group
United Kingdom
$374K +$8.96K +1,045 +2%
Group One Trading
88
Group One Trading
Illinois
$356K -$265K -30,846 -40%
NSEDCP
89
NJ State Employees Deferred Compensation Plan
New Jersey
$312K
CG
90
Clinton Group
New York
$312K +$24.2K +2,821 +8%
William Blair & Company
91
William Blair & Company
Illinois
$292K -$222K -25,900 -41%
PPA
92
Parametric Portfolio Associates
Washington
$256K +$8.04K +937 +3%
Cambridge Investment Research Advisors
93
Cambridge Investment Research Advisors
Iowa
$254K -$1.07K -125 -0.4%
BCM
94
Bourgeon Capital Management
Connecticut
$238K +$77.2K +9,000 +42%
ACH
95
ArrowMark Colorado Holdings
Colorado
$228K
HCM
96
Highbridge Capital Management
New York
$225K +$248K +28,872 New
Canada Pension Plan Investment Board
97
Canada Pension Plan Investment Board
Ontario, Canada
$218K +$89.2K +10,400 +59%
Citigroup
98
Citigroup
New York
$215K -$766K -89,278 -76%
Public Employees Retirement Association of Colorado
99
Public Employees Retirement Association of Colorado
Colorado
$212K
SGAM
100
Smith Group Asset Management
Texas
$210K -$858 -100 -0.4%

ACHN Hedge Fund Activity: Q2 2016 in Review

147 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q2 2016, worth a combined $852M — down 0.6% from $858M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ACHN and 17 opened new positions — a net loss of 3 holders — while 44 trimmed existing stakes and 55 added.

The largest buyer was Goldman Sachs, adding an estimated $11.9M. The largest seller was Janus Henderson Investors US, cutting an estimated $9.15M.

  • 147 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q2 2016, down from 153 in Q1 2016.
  • Funds reported $852M of Achillion Pharmaceuticals stock for Q2 2016, down 0.6% quarter-over-quarter.
  • 17 funds opened new Achillion Pharmaceuticals positions in Q2 2016 and 20 closed out, a net change of -3 holders.
  • The largest Achillion Pharmaceuticals buyer in Q2 2016 was Goldman Sachs, an estimated $11.9M added.
  • The largest Achillion Pharmaceuticals seller in Q2 2016 was Janus Henderson Investors US, an estimated $9.15M sold.

Based on aggregated 13F filings for Q2 2016.